Top

Published in:

01-04-2009

Comparative Neuroprotective Effects of Rasagiline and Aminoindan with Selegiline on Dexamethasone-Induced Brain Cell Apoptosis

Authors: Shawna Tazik, Shakevia Johnson, Deyin Lu, Chandra Johnson, Moussa B. H. Youdim, Craig A. Stockmeier, Xiao-Ming Ou

Published in: Neurotoxicity Research | Issue 3/2009

Abstract

Stress can affect the brain and lead to depression; however, the molecular pathogenesis is unclear. An association between stress and stress-induced hypersecretion of glucocorticoids occurs during stress. Dexamethasone (a synthetic glucocorticoid steroid) has been reported to induce apoptosis and increase the activity of monoamine oxidase (MAO) (Youdim et al. 1989). MAO is an enzyme for the degradation of aminergic neurotransmitters; dopamine, noradrenaline and serotonin and dietary amines and MAO inhibitors are classical antidepressant drugs. In this study, we have compared the ability of rasagiline (Azilect) and its main metabolite, R-aminoindan with selegiline (Deprenyl) in prevention of dexamethasone-induced brain cell death employing human neuroblastoma SH-SY5Y cells and glioblastoma 1242-MG cells. Dexamethasone reduced cell viability as measured by MTT test, but rasagiline, selegiline, and 1-R-aminoindan could significantly prevent dexamethasone-induced brain cell death. Among three drugs, rasagiline had the highest neuroprotective effect. Furthermore, the inhibitory effects of these drugs on MAO B catalytic activity and on apoptotic DNA damage (TUNEL staining) were examined. Rasagiline exhibited highest inhibition on MAO B enzymatic activity and prevention on DNA damage as compared to selegiline and 1-R-aminoindan. In summary, the greater neuroprotective effect of rasagiline may be associated with the combination of the parent drug and its metabolite 1-R-aminoindan.

Bar-Am O, Weinreb O, Amit T, Youdim MB (2005) Regulation of Bcl-2 family proteins, neurotrophic factors, and APP processing in the neurorescue activity of propargylamine. FASEB J 19:1899–1901PubMed

Bar-Am O, Amit T, Youdim MB (2007) Aminoindan and hydroxyaminoindan, metabolites of rasagiline and ladostigil, respectively, exert neuroprotective properties in vitro. J Neurochem 103:500–508PubMedCrossRef

Carlo P, Violani E, Del Rio M, Olasmaa M, Santagati S, Maggi A, Picotti GB (1996) Monoamine oxidase B expression is selectively regulated by dexamethasone in cultured rat astrocytes. Brain Res 711:175–183PubMedCrossRef

Carlsson A, Adolfsson R, Aquilonius SM, Gottfries CG, Oreland L, Svennerholm L, Winblad B (1980) Biogenic amines in human brain in normal aging, senile dementia, and chronic alcoholism. Adv Biochem Psychopharmacol 23:295–304PubMed

de Kloet ER, Reul JM, Sutanto W (1990) Corticosteroids and the brain. J Steroid Biochem Mol Biol 37:387–394PubMedCrossRef

Dolmatov IY, Dolmatova LS, Shitkova OA, Kovaleva AL (2004) Dexamethasone-induced apoptosis in phagocytes of holothurians. Taylor & Francis Group, London

Duval F, Mokrani MC, Monreal-Ortiz JA, Fattah S, Champeval C, Schulz P, Macher JP (2006) Cortisol hypersecretion in unipolar major depression with melancholic and psychotic features: dopaminergic, noradrenergic and thyroid correlates. Psychoneuroendocrinology 31:876–888PubMedCrossRef

Edelstein SB, Breakefield XO (1986) Monoamine oxidases A and B are differentially regulated by glucocorticoids and “aging” in human skin fibroblasts. Cell Mol Neurobiol 6:121–150PubMedCrossRef

Fernandez HH, Chen JJ (2007) Monamine oxidase inhibitors: current and emerging agents for Parkinson disease. Clin Neuropharmacol 30:150–168PubMedCrossRef

Geha RM, Rebrin I, Chen K, Shih JC (2001) Substrate and inhibitor specificities for human monoamine oxidase A and B are influenced by a single amino acid. J Biol Chem 276:9877–9882PubMedCrossRef

Glick RD, Medary I, Aronson DC, Scotto KW, Swendeman SL, La Quaglia MP (2000) The effects of serum depletion and dexamethasone on growth and differentiation of human neuroblastoma cell lines. J Pediatr Surg 35:465–472PubMedCrossRef

Goodnick PJ (2007) Seligiline transdermal system in depression. Expert Opin Pharmacother 8:59–64PubMedCrossRef

Hughes (2008) New hope for Parkinson’s disease progression delay. Nat Rev Drug Discov 7:791CrossRef

Jacobs CM, Trinh MD, Rootwelt T, Lomo J, Paulsen RE (2006) Dexamethasone induces cell death which may be blocked by NMDA receptor antagonists but is insensitive to Mg²⁺ in cerebellar granule neurons. Brain Res 1070:116–123PubMedCrossRef

Johnson S, Williams AN, Johnson C, Ou XM (2007) The effects of antidepressant drug on ethanol-induced cell death. Drug Discov Ther 1:130–135

Kato M, Katayama T, Iwata H, Yamamura M, Matsuoka Y, Narita H (1998) In vivo characterization of T-794, a novel reversible inhibitor of monoamine oxidase-A, as an antidepressant with a wide safety margin. J Pharmacol Exp Ther 284:983–990PubMed

Lakhani SA, Masud A, Kuida K, Porter GA Jr, Booth CJ, Mehal WZ, Inayat I, Flavell RA (2006) Caspases 3 and 7: key mediators of mitochondrial events of apoptosis. Science 311:847–851PubMedCrossRef

Lee AL, Ogle WO, Sapolsky RM (2002) Stress and depression: possible links to neuron death in the hippocampus. Bipolar Disord 4:117–128PubMedCrossRef

Malorni W, Giammarioli AM, Matarrese P, Pietrangeli P, Agostinelli E, Ciaccio A, Grassilli E, Mondovi B (1998) Protection against apoptosis by monoamine oxidase A inhibitors. FEBS Lett 426:155–159PubMedCrossRef

Mann JJ, Kaplan RD, Bird ED (1986) Elevated postmortem monoamine oxidase B activity in the caudate nucleus in Huntington’s disease compared to schizophrenics and controls. J Neural Transm 65:277–283PubMedCrossRef

Maruyama W, Akao Y, Youdim MB, Davis BA, Naoi M (2001) Transfection-enforced Bcl-2 overexpression and an anti-Parkinson drug, rasagiline, prevent nuclear accumulation of glyceraldehyde-3-phosphate dehydrogenase induced by an endogenous dopaminergic neurotoxin, N-methyl(R)salsolinol. J Neurochem 78:727–735PubMedCrossRef

Murphy BE (1997) Antiglucocorticoid therapies in major depression: a review. Psychoneuroendocrinology 22:S125–S132PubMedCrossRef

Ou XM, Chen K, Shih JC (2006a) Glucocorticoid and androgen activation of monoamine oxidase A is regulated differently by R1 and Sp1. J Biol Chem 281:21512–21525PubMedCrossRef

Ou XM, Chen K, Shih JC (2006b) Monoamine oxidase A and repressor R1 are involved in apoptotic signaling pathway. Proc Natl Acad Sci U S A 103:10923–10928PubMedCrossRef

Paterson IA, Barber AJ, Gelowitz DL, Voll C (1997) (-)Deprenyl reduces delayed neuronal death of hippocampal pyramidal cells. Neurosci Biobehav Rev 21:181–186PubMedCrossRef

Phillips AJ, Sudbery I, Ramsdale M (2003) Apoptosis induced by environmental stresses and amphotericin B in Candida albicans. Proc Natl Acad Sci USA 100:14327–14332PubMedCrossRef

Robinson DS, Amsterdam JD (2007) The selegiline transdermal system in major depressive disorder: a systematic review of safety and tolerability. J Affect Disord 105:15–23PubMedCrossRef

Saura J, Luque JM, Cesura AM, Da Prada M, Chan-Palay V, Huber G, Loffler J, Richards JG (1994) Increased monoamine oxidase B activity in plaque-associated astrocytes of Alzheimer brains revealed by quantitative enzyme radioautography. Neuroscience 62:15–30PubMedCrossRef

Schneider G, Oepen H, von Wedel HR (1981) Monoamine oxidase activity in brain regions and organs of patients with Parkinson’s disease and Huntington’s disease and serum MAO activity of patients with Huntington’s disease as compared with neurologically healthy individuals. Arch Psychiatr Nervenkr 230:5–15PubMedCrossRef

Senatorov VV, Charles V, Reddy PH, Tagle DA, Chuang DM (2003) Overexpression and nuclear accumulation of glyceraldehyde-3-phosphate dehydrogenase in a transgenic mouse model of Huntington’s disease. Mol Cell Neurosci 22:285–297PubMedCrossRef

Shih JC, Chen K, Ridd MJ (1999) Monoamine oxidase: from genes to behavior. Annu Rev Neurosci 22:197–217PubMedCrossRef

Slotkin TA, Seidler FJ, Ritchie JC (1998) Effects of aging and glucocorticoid treatment on monoamine oxidase subtypes in rat cerebral cortex: therapeutic implications. Brain Res Bull 47:345–348PubMedCrossRef

Tariot PN, Cohen RM, Sunderland T, Newhouse PA, Yount D, Mellow AM, Weingartner H, Mueller EA, Murphy DL (1987) L-deprenyl in Alzheimer’s disease. Preliminary evidence for behavioral change with monoamine oxidase B inhibition. Arch Gen Psychiatry 44:427–433PubMed

Tatton WG, Chalmers-Redman RM, Elstner M, Leesch W, Jagodzinski FB, Stupak DP, Sugrue MM, Tatton NA (2000) Glyceraldehyde-3-phosphate dehydrogenase in neurodegeneration and apoptosis signaling. J Neural Transm Suppl 60:77–100PubMed

Volz HP, Gleiter CH (1998) Monoamine oxidase inhibitors. A perspective on their use in the elderly. Drugs Aging 13:341–355PubMedCrossRef

Weinreb O, Amit T, Bar-Am O, Chillag-Talmor O, Youdim MB (2005) Novel neuroprotective mechanism of action of rasagiline is associated with its propargyl moiety: interaction of Bcl-2 family members with PKC pathway. Ann NY Acad Sci 1053:348–355PubMedCrossRef

Wolkowitz OM, Reus VI (1999) Treatment of depression with antiglucocorticoid drugs. Psychosom Med 61:698–711PubMed

Youdim MB (2006) The path from anti Parkinson drug selegiline and rasagiline to multifunctional neuroprotective anti Alzheimer drugs ladostigil and m30. Curr Alzheimer Res 3:541–550PubMedCrossRef

Youdim MB, Banerjee DK, Kelner K, Offutt L, Pollard HB (1989) Steroid regulation of monoamine oxidase activity in the adrenal medulla. FASEB J 3:1753–1759PubMed

Youdim MB, Gross A, Finberg JP (2001a) Rasagiline [N-propargyl-1R(+)-aminoindan], a selective and potent inhibitor of mitochondrial monoamine oxidase B. Br J Pharmacol 132:500–506PubMedCrossRef

Youdim MB, Wadia A, Tatton W, Weinstock M (2001b) The anti-Parkinson drug rasagiline and its cholinesterase inhibitor derivatives exert neuroprotection unrelated to MAO inhibition in cell culture and in vivo. Ann NY Acad Sci 939:450–458PubMedCrossRef

Youdim MB, Maruyama W, Naoi M (2005a) Neuropharmacological, neuroprotective and amyloid precursor processing properties of selective MAO-B inhibitor antiparkinsonian drug, rasagiline. Drugs Today (Barc) 41:369–391CrossRef

Youdim MB, Bar-Am O, Yogev-Falach M, Weinreb O, Maruyama W, Naoi M, Amit T (2005b) Rasagiline: neurodegeneration, neuroprotection, and mitochondrial permeability transition. J Neurosci Res 79:172–179PubMedCrossRef

Youdim MB, Edmondson D, Tipton KF (2006) The therapeutic potential of monoamine oxidase inhibitors. Nat Rev Neurosci 7:295–309PubMedCrossRef

Title: Comparative Neuroprotective Effects of Rasagiline and Aminoindan with Selegiline on Dexamethasone-Induced Brain Cell Apoptosis
Authors: Shawna Tazik
Shakevia Johnson
Deyin Lu
Chandra Johnson
Moussa B. H. Youdim
Craig A. Stockmeier
Xiao-Ming Ou
Publication date: 01-04-2009
Publisher: Springer-Verlag
Published in: Neurotoxicity Research / Issue 3/2009
Print ISSN: 1029-8428
Electronic ISSN: 1476-3524
DOI: https://doi.org/10.1007/s12640-009-9030-4

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Comparative Neuroprotective Effects of Rasagiline and Aminoindan with Selegiline on Dexamethasone-Induced Brain Cell Apoptosis

Abstract

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 3/2009

Methamphetamine Induces Long-Term Alterations in Reactivity to Environmental Stimuli: Correlation with Dopaminergic and Serotonergic Toxicity

P2X7 Nucleotide Receptor is Coupled to GSK-3 Inhibition and Neuroprotection in Cerebellar Granule Neurons

Neonatal Fluoxetine Exposure Affects the Neuronal Structure in the Somatosensory Cortex and Somatosensory-Related Behaviors in Adolescent Rats

Methylene Blue Provides Behavioral and Metabolic Neuroprotection Against Optic Neuropathy

Potential of Choroid Plexus Epithelial Cell Grafts for Neuroprotection in Huntington’s Disease: What Remains Before Considering Clinical Trials

Small-Molecule Mediated Neuroprotection in an In Situ Model of Tauopathy